362 research outputs found

    X-ray observations of a flare in NGC4151 from OSO-8

    Get PDF
    The 2-60 keV flux from NGC4151 changed by a factor of two on a timescale of 1.5 days. No fluctuations were detected in excess of a factor of three on timescales less than four hours. During a total observation of approximately 11 days there were no statistically significant changes in spectral shape. The spectrum was fitted by a power law with photon index alpha approximately 1.42 + or - 0.06 and column density N sub H approximately 7.5 + or - 0.5 x 10 to the 22d power at/cu cm. A 2 sigma residual to this fit implies fluorescent Fe line emission with E. W. approximately 240 eV. Both synchrotron self-Compton and thermal Compton models are consistent with the X-ray data

    Linear AM Decomposition for Sinusoidal Audio Coding

    Get PDF

    Subspace-based Fundamental Frequency Estimation

    Get PDF
    Publication in the conference proceedings of EUSIPCO, Viena, Austria, 200

    Mean square performance evaluation in frequency domain for an improved adaptive feedback cancellation in hearing aids

    Get PDF
    We consider an adaptive linear prediction based feedback canceller for hearing aids that exploits two (an external and a shaped) noise signals for a bias-less adaptive estimation. In particular, the bias in the estimate of the feedback path is reduced by synthesizing the high-frequency spectrum of the reinforced signal using a shaped noise signal. Moreover, a second shaped (probe) noise signal is used to reduce the closed-loop signal correlation between the acoustic input and the loudspeaker signal at low frequencies. A power-transfer-function analysis of the system is provided, from which the effect of the system parameters and adaptive algorithms [normalized least mean square (NLMS) and recursive least square (RLS)] on the rate of convergence, the steady-state behaviour and the stability of the feedback canceller is explicitly found. The derived expressions are verified through computer simulations. It is found that, as compared to feedback canceller without probe noise, the cost of achieving an unbiased estimate of the feedback path using the feedback canceller with probe noise is a higher steady-state misadjustment for the RLS algorithm, whereas a slower convergence and a higher tracking error for the NLMS algorithm

    Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer

    Get PDF
    Detection of methylated free-circulating DNA (mfcDNA) for hyperplastic polyposis 1 (HPP1) in blood is correlated with a poor prognosis for patients with metastatic colorectal cancers (mCRC). Here, we analyzed the plasma levels of HPP1 mfcDNA in mCRC patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1 mfcDNA is a suitable prognostic and response biomarker. From 467 patients of the prospective clinical study AIO-KRK-0207, mfcDNA was isolated from plasma samples at different time points and bisulfite-treated mfcDNA was quantified using methylation specific PCR. About 337 of 467 patients had detectable levels for HPP1 mfcDNA before start of treatment. The detection was significantly correlated with poorer overall survival (OS) (HR = 1.86; 95%CI 1.37-2.53). About 2-3 weeks after the first administration of combination chemotherapy, HPP1 mfcDNA was reduced to non-detectable levels in 167 of 337 patients. These patients showed a better OS compared with patients with continued detection of HPP1 mfcDNA (HR HPP1(sample 1: pos/ sample 2: neg) vs. HPP1(neg/neg) = 1.41; 95%CI 1.00-2.01, HPP1(neg,pos/pos) vs. HPP1(neg/neg) = 2.60; 95%CI 1.86-3.64). Receiver operating characteristic analysis demonstrated that HPP1 mfcDNA discriminates well between patients who do (not) respond to therapy according to the radiological staging after 12 or 24 weeks (AUC = 0.77 or 0.71, respectively). Detection of HPP1 mfcDNA can be used as a prognostic marker and an early marker for response (as early as 3-4 weeks after start of treatment compared with radiological staging after 12 or 24 weeks) to identify patients who will likely benefit from a combination chemotherapy with bevacizumab.info:eu-repo/semantics/publishedVersio
    • …
    corecore